Page last updated: 2024-11-07

rb 104

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

RB 104: potent inhibitor of EC 3.4.24.11; used to detect nanogram quantities of the enzyme by inhibitor gel electrophoresis; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID132708
MeSH IDM0203808

Synonyms (9)

Synonym
benzenepropanoic acid, 4-hydroxy-alpha-(2-((3-(hydroxyamino)-3-oxo-1-(phenylmethyl)propyl)amino)-2-oxoethyl)-3-iodo-
rb104
145253-48-1
rb-104
2-((3-iodo-4-hydroxy)phenylmethyl)-4-n-(3-(hydroxyamino-3-oxo-1-phenylmethyl)propyl)amino-4-oxobutanoic acid
rb 104
4-[[4-(hydroxyamino)-4-oxo-1-phenylbutan-2-yl]amino]-2-[(4-hydroxy-3-iodophenyl)methyl]-4-oxobutanoic acid
4-hydroxy-4-{[4-hydroxy-4-(hydroxyimino)-1-phenylbutan-2-yl]imino}-2-[(4-hydroxy-3-iodophenyl)methyl]butanoic acid
DTXSID10932545
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's6 (85.71)18.2507
2000's1 (14.29)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 26.66

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index26.66 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.18 (4.65)
Search Engine Demand Index29.12 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (26.66)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]